Control algorithms for closed-loop insulin delivery in type 1 diabetes have been mainly based on control engineering or artificial intelligence techniques. These, however, are not based on the physiology of the pancreas but seek to implement engineering solutions to biology. Developments in mathematical models of the β-cell physiology of the pancreas have described the glucose-induced insulin release from pancreatic β cells at a molecular level. This has facilitated development of a new class of bio-inspired glucose control algorithms that replicate the functionality of the biological pancreas. However, technologies for sensing glucose levels and delivering insulin use the subcutaneous route, which is nonphysiological and introduces some challenges. In this article, a novel glucose controller is presented as part of a bio-inspired artificial pancreas.
Methods:
A mathematical model of β-cell physiology was used as the core of the proposed controller. In order to deal with delays and lack of accuracy introduced by the subcutaneous route, insulin feedback and a gain scheduling strategy were employed. A United States Food and Drug Administration-accepted type 1 diabetes mellitus virtual population was used to validate the presented controller.
Results:
Premeal and postmeal mean ± standard deviation blood glucose levels for the adult and adolescent populations were well within the target range set for the controller [(70, 180) mg/dl], with a percent time in range of 92.8 ± 7.3% for the adults and 83.5 ± 14% for the adolescents.
Conclusions:
This article shows for the first time very good glucose control in a virtual population with type 1 diabetes mellitus using a controller based on a subcellular β-cell model.
KovatchevBAndersonSHeinemannLClarkeW. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care.2008;31 (6): 1160–4.
3.
BequetteBW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther.2005;7 (1): 28–47.
SteilGMRebrinKDarwinCHaririFSaadMF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes.2006;55 (12): 3344–50.
6.
HovorkaRCanonicoVChassinLJHaueterUMassi-BenedettiMFedericiM OrsiniPieberTRSchallerHCSchauppLVeringTWilinskaME. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Mea.2004;25 (4): 905–20.
7.
El-KhatibFHRussellSJNathanDMSutherlinRGDamianoER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med.2010;2 (27): 27ra27.
8.
AtlasENimriRMillerSGrunbergEAPhillipM. MD-logic artificial pancreas system: A pilot study in adults with type 1 diabetes. Diabetes Care.2010;33 (5): 1072–6.
9.
Campos-DelgadoDUHernández-OrdoñezMFematRGordillo-MoscosoA. Fuzzy-based controller for glucose regulation in type-1 diabetic patients by subcutaneous route. IEEE Trans Biomed Eng.2006;53 (11): 2201–10.
10.
MeadC. Analog VLSI and neural systems. Reading (MA): Addison-Wesley; 1989.
11.
GeorgiouJToumazouC. A 126-μW cochlear chip for a totally implantable system. IEEE J Solid State Circuit.2005;40 (2): 430–43.
12.
DegenaarPGrossmanNMemonMABurroneJDawsonMDrakakisENeilMNikolicK. Optobionic vision—a new genetically enhanced light on retinal prosthesis. J Neural Eng.2009;6 (3): 035007.
13.
ConstandinouTGGeorgiouJToumazouC. A neural implant ASIC for the restoration of balance in individuals with vestibular dysfunction. ISCAS 2009: IEEE International Symposium on Circuits and Systems; 2009 May 24–27; Taipei, Taiwan. p. 641–644.
14.
CaumoALuziL. First-phase insulin secretion: Does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab.2004;287 (3): E371–85.
15.
SteilGMPanteleonAERebrinK. Closed-loop insulin delivery — The path to physiological glucose control. Adv Drug Deliv Rev.2004;56 (2) 125–44.
16.
KeenanDBMastrototaroJJVoskanyanGSteilGM. Delays in minimally invasive continuous glucose monitoring devices: A review of current technology. J Diabetes Sci Technol.2009;3 (5): 1207–14.
17.
HeinemannL. Variability of insulin absorption and insulin action. Diabetes Technol Ther.2002;4 (5): 673–82.
BredaEToffoloGPolonskyKSCobelliC. Insulin release in impaired glucose tolerance: Oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes.2002;51 (Suppl 1): S227–33.
20.
OliverNGeorgiouPJohnstonDToumazouC. A benchtop closed-loop system controlled by a bio-inspired silicon implementation of the pancreatic beta cell. J Diabetes Sci Technol.2009;3 (6): 1419–24.
21.
PedersenMGBertramRShermanA. Intra- and inter-islet synchronization of metabolically driven insulin secretion. Biophys J.2005;89 (1): 107–19.
22.
BertuzziASalinariSMingroneG. Insulin granule trafficking in β-cells: Mathematical model of glucose-induced insulin secretion. Am J Physiol Endocrinol Metab.2007;293 (1): E396–409.
23.
ChenYWangSShermanA. Identifying the targets of the amplifying pathway for insulin secretion in pancreatic β-cells by kinetic modeling of granule exocytosis. Biophysical J.2008;95 (5): 2226–41.
24.
PedersenMGToffoloGMCobelliC. Cellular modeling: Insight into oral minimal models of insulin secretion. Am J Physiol Endocrinol Metab.2010;298 (3): E597–601.
25.
KovatchevBPBretonMManC DallaCobelliC. In silico preclinical trials: A proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol.2009;3 (1): 44–55.
26.
HovorkaRChassinLLuzioSDPlayleROwensDR. Pancreatic β-cell responsiveness during meal tolerance test: Model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab.1998;83 (3): 744–50.
27.
ToffoloGBredaECavaghanMKEhrmannDAPolonskyKSCobelliC. Quantitative indexes of β-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab.2001;280 (1): E2–10.
28.
CrettiALehtovirtaMBonoraEBrunatoBZentiMGTosiFCaputoMCarusoBGroopLCMuggeoMBonadonnaRC. Assessment of β-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. Eur J Clin Invest.2001;31 (5): 405–16.
29.
MariASchmitzOGastaldelliAOestergaardTNyholmBFerranniniE. Meal and oral glucose tests for assessment of β-cell function: Modeling analysis in normal subjects. Am J Physiol Endocrinol Metab.2002;283 (6): E1159–66.
30.
PedersenMGCorradinAToffoloGMCobelliC. A subcellular model of glucose-stimulated pancreatic insulin secretion. Philos Transact A Math Phys Eng Sci.2008;366 (1880): 3525–43.
31.
GrodskyGM. A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest.1972;51 (8): 2047–59.
32.
DassauEBequetteBWBuckinghamBADoyleFJ3rd. Detection of a meal using continuous glucose monitoring: Implications for an artificial β-cell. Diabetes Care.2008;31 (2): 295–300.
33.
DassauECameronFLeeHBequetteBWZisserHJovanovicLChaseHPWilsonDMBuckinghamBADoyleFJ3rd. Realtime hypoglycemia prediction suite using continuous glucose monitoring: A safety net for the artificial pancreas. Diabetes Care.2010;33 (6): 1249–54.
34.
WeinzimerSASteilGMSwanKLDziuraJKurtzNTamborlaneWV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care.2008;31 (5): 934–9.
35.
SteilGRebrinKMastrototaroJJ. Metabolic modelling and the closed-loop insulin delivery problem. Diabetes Res Clin Pract.2006;74 (Suppl 2): S183–6.
36.
LeeHBuckinghamBAWilsonDMBequetteBW. A closed loop artificial pancreas using model predictive control and a sliding meal size estimator. J Diabetes Sci Technol.2009;3 (5): 1082–90.
